Experimental cancer drug trial ends early
NCT ID NCT04272034
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Docrates Cancer Center
Helsinki, 00180, Finland
-
Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Ghent University Hospital
Ghent, 09000, Belgium
-
Guys and St Thomas Nhs Foundation Trust
London, SE1 9RT, United Kingdom
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Haukeland University Hospital
Bergen, 05051, Norway
-
Helsinki University Central Hospital
Helsinki, 00029, Finland
-
Imperial College Healthcare Nhs Trust - Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Institut Jules Bordet
Brussels, B-1070, Belgium
-
Karolinska University Hospital Solna
Solna, 17164, Sweden
-
Oslo University Hospital
Oslo, 00450, Norway
-
Prisma Health Cancer Institute Faris
Greenville, South Carolina, 29605, United States
-
Rigshospitalet Uni of Hospital of Copenhagen
Copenhagen, 02100, Denmark
-
Sahlgrenska University Hospital
Gothenburg, 41345, Sweden
-
St James University Hospital
Leeds, LS9 7TF, United Kingdom
-
Tampere University Hospital
Tampere, 33520, Finland
-
The Royal Marsden Hospital Nhs Trust London
London, SM2 5PT, United Kingdom
-
Turku University Hospital
Turku, 20520, Finland
-
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, 02650, Belgium
-
Universitair Ziekenhuis Brussel
Brussels, 01090, Belgium
-
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, 03000, Belgium
-
Uppsala Universitet - Akademiska Sjukhuset
Uppsala, 75185, Sweden
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?